PainChek Completes Submission for US FDA De Novo Regulatory Clearance for App; Shares Up 3%
MT Newswires Live
Jul 21
PainChek (ASX:PCK) completed its final submission to the US Food and Drug Administration for de novo regulatory clearance for its PainChek Adult app, which includes its artificial intelligence pain assessment tool, as a medical device in the country, according to a Monday Australian bourse filing.
The company expects a final decision on the clearance within 75 days.
The firm added that US partner agreements were already in place to support the commercialization of the app.
PainChek's shares were up almost 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.